Growth Metrics

Innoviva (INVA) Gross Profit (2011 - 2026)

Innoviva posted quarterly Gross Profit of $75.8 million for Q1 2026, up 3.43% year-on-year from $73.3 million in Q1 2025, and little changed on a QoQ basis from $75.5 million in Q3 2025.

Innoviva (INVA) has 9 years of Gross Profit data on file, last reported at $75.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Gross Profit rose 3.43% year-over-year to $75.8 million; the trailing twelve-month figure through Mar 2026 stood at $307.8 million (up 5.64% YoY), and the FY2025 full-year result was $307.7 million, up 3.87% from the prior year.
  • Gross Profit for Q1 2026 stood at $75.8 million, roughly flat from $75.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $85.0 million in Q2 2024 and bottomed at -$8.0 million in Q2 2023.
  • The 5-year median for Gross Profit is $67.3 million (2023), against an average of $45.3 million.
  • The widest annual swing landed in 2023, when Gross Profit tumbled 524.8%; it then soared 7573.63% in 2024.
  • A 5-year view of Gross Profit shows it stood at $1.3 million in 2022, then soared by 5073.77% to $67.3 million in 2023, then rose by 8.55% to $73.0 million in 2024, then rose by 3.47% to $75.5 million in 2025, then grew by 0.39% to $75.8 million in 2026.
  • The last three Gross Profit figures came in at $75.8 million (Q1 2026), $75.5 million (Q3 2025), and $83.1 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 75.83 Mn
Mar 31, 2026 75.83 Mn
Sep 30, 2025 75.54 Mn
Sep 30, 2025 75.54 Mn
Jun 30, 2025 83.15 Mn
Jun 30, 2025 83.15 Mn
Mar 31, 2025 73.32 Mn
Mar 31, 2025 73.32 Mn
Sep 30, 2024 73.01 Mn
Sep 30, 2024 73.01 Mn
Jun 30, 2024 84.99 Mn
Jun 30, 2024 84.99 Mn
Mar 31, 2024 60.09 Mn
Mar 31, 2024 60.09 Mn
Sep 30, 2023 67.26 Mn
Sep 30, 2023 67.26 Mn
Jun 30, 2023 -8.00 Mn
Jun 30, 2023 -8.00 Mn
Mar 31, 2023 -804,000.00
Mar 31, 2023 -804,000.00
Sep 30, 2022 1.30 Mn
Sep 30, 2022 1.30 Mn
Jun 30, 2022 1.88 Mn
Jun 30, 2022 1.88 Mn
Mar 31, 2022 1.24 Mn
Mar 31, 2022 1.24 Mn
Sep 30, 2021 97.86 Mn
Sep 30, 2021 97.86 Mn
Mar 31, 2014 592,000.00
Mar 31, 2014 592,000.00
Mar 31, 2013 1.32 Mn
Mar 31, 2013 1.32 Mn
Dec 31, 2011 5.36 Mn
Dec 31, 2011 5.36 Mn
Sep 30, 2011 6.43 Mn
Sep 30, 2011 6.43 Mn
Jun 30, 2011 5.21 Mn
Jun 30, 2011 5.21 Mn